Lantheus Holdings, Inc. (LNTH)

Market Cap	5.44B
Revenue (ttm)	1.37B
Net Income (ttm)	460.53M
Shares Out	69.31M
EPS (ttm)	6.55
PE Ratio	11.98
Forward PE	10.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	478,854
Open	80.53
Previous Close	80.00
Day's Range	78.43 - 81.00
52-Week Range	50.20 - 91.81
Beta	0.56
Analysts	Strong Buy
Price Target	99.17 (+26.33%)
Earnings Date	Aug 1, 2024

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 834
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH

Financial Performance

In 2023, LNTH's revenue was $1.30 billion, an increase of 38.65% compared to the previous year's $935.06 million. Earnings were $326.66 million, an increase of 1063.86%.

Analyst Forecast

According to 7 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $99.17, which is an increase of 26.33% from the latest price.

Price Target

$99.17

(26.33% upside)

Analyst Consensus: Strong Buy